Trial Profile
Phase II Trial of AZD9291 in First Line Treatment of Lung Cancer Harboring Activating EGFR Mutation From Circulating Tumor DNA and Second Line Treatment After Acquired Resistance With T790M Mutation Detected From Circulating Tumor DNA
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms LiquidLung-O
- 01 Aug 2021 Status changed from active, no longer recruiting to completed.
- 26 Sep 2018 Results assessing osimertinib in the first-line treatment of non-small cell lung cancer harboring activating EGFR mutation from circulating Tumor DNA presented at the 19th World Conference on Lung Cancer
- 16 Jul 2018 Status changed from recruiting to active, no longer recruiting.